Key result
Culprit TIMI 0-1 flow in multivessel NSTEMI linked to ~2.1-fold higher 1-year major cardiovascular events.
Why the study?
Does culprit vessel TIMI 0-1 flow increase the 1-year risk of MACE compared to TIMI 2-3 flow in NSTEMI patients with multivessel disease?
Cohort (n=474)
SLIM trial randomized NSTEMI patients with multivessel disease to complete or culprit-only revascularization (current study is a post-hoc analysis grouped by TIMI flow)
Does culprit vessel TIMI 0-1 flow increase the 1-year risk of MACE compared to TIMI 2-3 flow in NSTEMI patients with multivessel disease?
In NSTEMI patients with multivessel disease, culprit vessel TIMI 0-1 flow identifies an occlusive MI subgroup more frequently involving the circumflex artery that is not distinguished by routine admission ECG ST-deviation and carries more than double the adjusted risk of 1-year MACE.
Answers are grounded in this paper and cite their sources.
Culprit TIMI 0-1 flow flags higher-risk multivessel NSTEMI; hypothesis-generating for risk-stratified trials before practice change.
Occlusive myocardial infarction (OMI) is a specific, high-risk subgroup of non-ST elevation myocardial infarction. To estimate the impact of this clinical entity, this post-hoc analysis of the SLIM trial uses decreased TIMI flow (0 or 1) and patent flow (TIMI 2-3 flow) as surrogates to characterize these patient groups and their outcomes in a cohort with NSTEMI and multivessel coronary artery disease. The SLIM trial randomized NSTEMI patients with multivessel disease to complete or culprit-only revascularization; we included 474 patients with available angiographic data in the current analysis. One-year Major Adverse Cardiovascular Events (MACE: all-cause death, non-fatal MI, any revascularization, and stroke) were assessed using Kaplan-Meier survival analysis, and the association between study groups and outcomes was evaluated in crude and adjusted Cox proportional-hazards models. TIMI 0-1 patients were younger (62 vs. 67 years, p<0.001), predominantly male (84.9% vs. 69.3%, p<0.001), with higher baseline biomarker levels. Routine interpretation of admission ECGs failed to differentiate occlusion status (reported ST-deviation 32.1% vs. 33.2%, p = 0.835). In the TIMI 0-1 flow group, the circumflex artery was the culprit more often (45.3% vs. 27.7%, p < 0.001). Although unadjusted MACE at 1-year follow-up was comparable (p=0.061), adjusted models showed that decreased flow was associated with MACE at one year (MACE: aHR 2.09, p=0.026). This post-hoc analysis of the SLIM trial shows that TIMI 0-1 flow during the index procedure is an indicator for a high-risk subgroup of NSTEMI patients with multivessel disease who face a higher risk of MACE at one year.
No takes yet. Share an insight, caveat, or question.
Lux et al. (2026) conducted a cohort in Non-ST elevation myocardial infarction (NSTEMI) with multivessel coronary artery disease (n=474). Decreased culprit vessel flow (TIMI 0-1 flow / occlusive myocardial infarction) vs. Patent culprit vessel flow (TIMI 2-3 flow) was evaluated on One-year Major Adverse Cardiovascular Events (MACE: all-cause death, non-fatal MI, any revascularization, and stroke) (aHR 2.09, p=0.026). Culprit vessel TIMI 0-1 flow in NSTEMI with multivessel disease was associated with higher 1-year major cardiovascular events after adjustment compared to TIMI 2-3 flow.
Synapse has enriched 10 related papers. Consider them for comparative context: